Welcome to our dedicated page for Oruka Therapeutics SEC filings (Ticker: ORKA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a clinical-stage biotech filing can feel like decoding an immunology textbook. Oruka Therapeutics’ 10-K details half-life extension technology, while each 8-K announces new trial data or financing rounds that can move the share price overnight. Finding R&D burn rates, dilution clauses, or executive grants across hundreds of pages is time-consuming and error-prone.
Our platform removes that friction. Stock Titan delivers AI-powered summaries for every Oruka Therapeutics SEC document—so understanding Oruka Therapeutics SEC documents with AI becomes immediate. Get real-time alerts the moment an Oruka Therapeutics 8-K material event is posted, review an Oruka Therapeutics quarterly earnings report 10-Q filing with plain-English highlights, or track Oruka Therapeutics Form 4 insider transactions real-time without scanning multiple PDFs. Whether you need the Oruka Therapeutics annual report 10-K simplified or a quick Oruka Therapeutics earnings report filing analysis, our expert layer translates biotech jargon into actionable facts.
Dig deeper into what matters for a pipeline company: cash runway, trial endpoints, and insider confidence. Use our dashboard to:
- Monitor Oruka Therapeutics insider trading Form 4 transactions and spot trends in executive stock activity.
- Compare quarter-over-quarter R&D spending across 10-Qs.
- Surface key compensation metrics inside the latest Oruka Therapeutics proxy statement executive compensation.
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing monoclonal antibodies for psoriasis and inflammatory diseases. As of June 30, 2025 the company reported $65.4 million in cash, $286.1 million in marketable securities (totaling $351.5 million), total assets of $357.4 million and stockholders' equity of $343.6 million. For the three and six months ended June 30, 2025 the company recorded net losses of $24.6 million and $45.6 million, respectively, and used $44.0 million of cash in operating activities during the first half of 2025. Research and development was the primary expense, totaling $44.0 million for six months.
The company advanced its pipeline: ORKA-001 (anti-IL-23p19) completed Phase 1 dosing in healthy volunteers, received FDA IND and Health Canada CTA clearances and commenced Phase 2a dosing with the first patient dosed subsequent to the quarter end; ORKA-002 (anti-IL-17A/F) initiated Phase 1 dosing. Oruka holds exclusive licenses with Paragon that include milestone payments (up to $12.0 million clinical and $10.0 million regulatory per program) and low single-digit royalties; it has expensed $4.0 million for each license. Management expects existing cash, cash equivalents and marketable securities to fund operating plans for at least twelve months from issuance of these financial statements.
On July 1, 2025, Oruka Therapeutics, Inc. (ORKA) filed a Form 4 reporting that Chief Operating Officer Laura Lee Sandler received an employee stock option covering 25,000 shares of common stock at an exercise price of $11.80 per share. The option expires on June 30, 2035 and vests 25 % on July 1, 2026, with the remaining 75 % vesting in equal monthly installments thereafter (1⁄48 per month). After the grant, Sandler beneficially owns 25,000 derivative securities; no non-derivative share transactions were disclosed. The filing reflects an incentive-based award rather than an open-market purchase or sale, resulting in no immediate cash flow or share-count impact for investors.
On 07/01/2025, Oruka Therapeutics, Inc. (ORKA) filed a Form 3 reporting the initial beneficial ownership of its newly appointed Chief Operating Officer, Laura Lee Sandler.
- Direct ownership: 213,084 shares of common stock.
- Derivative securities: • Warrant covering 99,996 shares at an exercise price of $7.80, expiring 07/14/2034. Vesting schedule: 25% on 04/03/2025, remaining shares vest monthly over the subsequent three years. • Employee stock option for 137,500 shares at $12.50, expiring 01/21/2035; vests 1/48 monthly beginning 01/01/2025.
- Potential total ownership: 450,580 shares if all derivatives vest and are exercised.
The disclosure signals meaningful insider alignment through equity ownership and a performance-linked vesting structure. No other transactions or financial metrics were included in this filing.
FAQ
What is the current stock price of Oruka Therapeutics (ORKA)?
What is the market cap of Oruka Therapeutics (ORKA)?
